Chemo Pharma Laboratories Limited (CHEMOPH.BO)
INR 97.61
(-4.97%)
INR 97.61
(-4.97%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 18.38 Million | 2.95 Million | 7.88 Million | 5.48 Million | 9.96 Million |
| Cost of Revenue | - | 5200.00 | 8500.00 | 23.3 Thousand | 16.62 Thousand |
| Gross Profit | 18.38 Million | 2.94 Million | 7.88 Million | 5.45 Million | 9.95 Million |
| Operating Expenses | 1.94 Million | 2.04 Million | 4.23 Million | 1.6 Million | 5 Million |
| Selling, General and Administrative Expenses | 1.67 Million | 305.05 Thousand | 1.28 Million | 329.25 Thousand | 46.25 Thousand |
| Research and Development Expenses | - | - | - | - | - |
| Other Expenses | - | 2.95 Million | 980.00 | 6.68 Million | - |
| Cost and Expenses | 1.94 Million | 2.04 Million | 4.23 Million | 1.6 Million | 5.02 Million |
| Operating Income | 16.43 Million | 5.04 Million | 2.47 Million | 3.7 Million | 5.07 Million |
| Interest Expense | - | 108.3 Thousand | - | 750.00 | - |
| Income Tax Expense | 4.43 Million | 258.93 Thousand | -1.95 Million | 606.25 Thousand | 789.78 Thousand |
| Earnings before Tax | 16.43 Million | 731.97 Thousand | 3.64 Million | 3.1 Million | 4.94 Million |
| Net Income | 12 Million | 473.03 Thousand | 5.59 Million | 2.5 Million | 4.15 Million |
| Earnings Per Share Basic | 8.00 | 0.32 | 3.73 | 1.67 | 2.77 |
| Earnings Per Share Diluted | 8.00 | 0.32 | 3.73 | 1.67 | 2.77 |
| Weighted Average Shares Outstanding | 1.5 Million | 1.47 Million | 1.5 Million | 1.5 Million | 1.5 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.5 Million | 1.47 Million | 1.5 Million | 1.5 Million | 1.5 Million |
| Gross Margin | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| EBIT Margin | 0.90 | 1.75 | 0.34 | 0.72 | 0.53 |
| Profit Margin | 0.65 | 0.16 | 0.71 | 0.46 | 0.42 |
| EBITDA | 16.51 Million | 971.28 Thousand | 2.66 Million | 3.94 Million | - |
| Earnings Before Tax Margin | 0.89 | 1.71 | 0.31 | 0.68 | 0.51 |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 3.01 Million | 2.46 Million | 18.38 Million | 7.02 Million | 4.59 Million | 4.29 Million |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | 3.01 Million | 2.46 Million | 18.38 Million | 7.02 Million | 4.59 Million | 4.29 Million |
| Operating Expenses | 551.99 Thousand | 953 Thousand | 1.94 Million | 258 Thousand | 205 Thousand | 530.99 Thousand |
| Selling, General and Administrative Expenses | 538 Thousand | 878 Thousand | - | 183 Thousand | 130 Thousand | 510 Thousand |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | 2.46 Million | 18.38 Million | 7.02 Million | 4.59 Million | - |
| Cost and Expenses | 551.99 Thousand | 953 Thousand | 1.94 Million | 258 Thousand | 205 Thousand | 530.99 Thousand |
| Operating Income | 2.46 Million | 1.51 Million | 16.43 Million | 6.76 Million | 4.39 Million | 3.76 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | 4.42 Million | 4.43 Million | 4000.00 | - | - |
| Earnings before Tax | 2.46 Million | 1.51 Million | 16.43 Million | 6.76 Million | 4.39 Million | 3.76 Million |
| Net Income | 2.46 Million | -2.91 Million | 12 Million | 6.76 Million | 4.39 Million | 3.76 Million |
| Earnings Per Share Basic | 1.64 | -1.94 | - | 4.51 | 2.93 | 2.51 |
| Earnings Per Share Diluted | 1.64 | -1.94 | - | 4.51 | 2.93 | 2.51 |
| Weighted Average Shares Outstanding | 1.5 Million | 1.5 Million | 1.5 Million | 1.49 Million | 1.49 Million | 1.49 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.5 Million | 1.5 Million | 1.5 Million | 1.49 Million | 1.49 Million | 1.49 Million |
| Gross Margin | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| EBIT Margin | 0.82 | 0.62 | - | 0.97 | 0.96 | 0.88 |
| Profit Margin | 0.82 | -1.18 | 0.65 | 0.96 | 0.96 | 0.88 |
| EBITDA | 2.48 Million | 1.53 Million | - | 6.78 Million | 4.41 Million | 3.79 Million |
| Earnings Before Tax Margin | 0.82 | 0.61 | 0.89 | 0.96 | 0.96 | 0.88 |
TUP
U
MALDF
BNVIF
5026
NNN1